Coherus Oncology, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
CHRS$0.82+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · September 30, · · December 31, | ||||||
| · · 2026 · · 2025 | ||||||
| Assets · · · · · | ||||||
| Current assets: · · · · | ||||||
| Cash and cash equivalents | | $53,487 | | $88,879 | ||
| Investments in marketable securities | | | 30,142 | | | 83,246 |
| Trade receivables, net | | | 13,720 | | 17,815 | |
| TSA receivables, net | | | 196 | | | 603 |
| Inventory | | | 4,824 | | 3,172 | |
| Prepaid manufacturing | | 5,932 | | 6,758 | ||
| Other prepaids and current assets | | | 5,826 | | 6,233 | |
| Total current assets | | 114,127 | | 206,706 | ||
| Property and equipment, net | | 652 | | 1,345 | ||
| Inventory, non-current | | | 9,354 | | | — |
| Intangible assets, net | | 44,364 | | 46,239 | ||
| Other assets, non-current | | 2,607 | | 4,053 | ||
| Total assets | | $171,104 | | $258,343 | ||
| | | | | | | |
| Liabilities and Stockholders’ Equity | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $14,506 | | $9,915 | ||
| Accrued rebates, fees and reserves | | | 13,746 | | 30,397 | |
| TSA payables and accrued liabilities | | | 19,638 | | | 65,065 |
| Accrued compensation | | | 11,971 | | 14,579 | |
| Accrued and other current liabilities | | | 15,775 | | 20,430 | |
| Total current liabilities | | | 75,636 | | 140,386 | |
| Term loans, non-current | | | 52,551 | | | 37,051 |
| Other liabilities, non-current | | | 17,668 | | 19,892 | |
| Total liabilities | | 145,855 | | 197,329 | ||
| Commitments and contingencies (Note 9) | | | | | ||
| Stockholders’ equity: | | | | | ||
| Preferred stock ($0.0001 par value; shares authorized: 5,000,000; shares issued and outstanding: 0 at September 30, 2026 and December 31, 2025) | | | — | | | — |
| Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 154,534,632 and 121,154,925 at September 30, 2026 and December 31, 2025, respectively) | | 15 | | 12 | ||
| Additional paid-in capital | | 1,506,782 | | 1,444,166 | ||
| Accumulated other comprehensive loss | | (287) | | (195) | ||
| Accumulated deficit | | (1,481,261) | | (1,382,969) | ||
| Total stockholders' equity | | 25,249 | | 61,014 | ||
| Total liabilities and stockholders’ equity | | $171,104 | | $258,343 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.